Status:
UNKNOWN
Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer
Lead Sponsor:
Sichuan Provincial People's Hospital
Collaborating Sponsors:
Jiangsu HengRui Medicine Co., Ltd.
Conditions:
Colorectal Cancer
Neoadjuvant Therapy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Apatinib has been proved to be effective and safe among patients in advanced colorectal cancer in several trials. the investigators aimed to evaluate its efficacy and safety as the neoadjuvant therapy...
Detailed Description
Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhib...
Eligibility Criteria
Inclusion
- Age of 18 years or older.
- Histological or cytological confirmation of adenocarcinoma of the colon or/and rectum;
- Stage TxNxM1 (truly metastatic disease) with liver metastases only.
- Patients should be voluntary to the trial and provide with signed informed consent.
- The researchers believe patients can benefit from the study.
Exclusion
- Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories.
- Pregnant or lactating women
- Patients with Apatinib contraindications
- Patients of doctors considered unsuitable for the trial
Key Trial Info
Start Date :
January 31 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03377842
Start Date
January 31 2018
End Date
September 1 2020
Last Update
December 19 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.